Searchable abstracts of presentations at key conferences in endocrinology

ea0089t3 | Trials In Progress | NANETS2022

Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Carcinoid Syndrome

Chauhan, MD Aman , Shaheen, MD Shagufta , Usiskin, MD Keith , Odueyungbo, PhD Ade , Mui, BSc Cosina , Dillon, MD Joseph

Background: Neuroendocrine tumors (NETs) are classified as functional or non-functional based on the presence of characteristic symptoms, related to tumoral secretion of biologically active peptides or amines. Carcinoid Syndrome (CS) is the commonest functional NET syndrome, seen at diagnosis in 19% of patients. It is characterized in over 80% of cases by watery diarrhea (mainly due to serotonin hypersecretion) or cutaneous flushing. Somatostatin is a neuropeptide that inhibit...